Smallpox Vaccine Program Launched Amid
Concerns Raised by Expert Panel, Unions
Joan Stephenson, PhD

The Centers for Disease Control and Prevention (CDC) began shipping
smallpox vaccine to some states on January 22, launching the first phase of
a federal program to vaccinate a half million US health care workers. The
vaccine is being offered on a voluntary basis to those who would be the most
likely to respond to a terrorist attack with smallpox
emergency
department personnel and people working on special smallpox response teams.
Under the program, which was announced by President Bush in December,
states could begin inoculating volunteers on January 24. Another 10 million
people, including additional health care workers and emergency medical
personnel, firefighters, and police, will be offered the vaccine during
phase 2 of the program. Mandatory immunization of 500 000 military personnel
was already under way last December.
QUESTIONS ABOUT COMPENSATION

The effort remained on schedule despite pointed questions raised days
earlier in a report by an expert panel convened by the Institute of Medicine
(IOM) at the request of the CDC and unions representing thousands of health
care workers. (The Institute of Medicine's report, Review of the Centers
for Disease Control and Prevention's Smallpox Vaccination Program
Implementation is available on-line at
http://www.nap.edu/catalog/10601.html.)


The smallpox vaccine contains live vaccinia, which like
smallpox (variola) is a
member of the Orthopoxvirus family. It is administered with a
bifurcated needle, which is dipped into the vaccine solution and used to
prick the skin several times. (Photo credit: Fred Murphy, PhD/Silvia
Whitfield, CDC [left side], and CDC [right side]) |
High on the list of concerns was the program's lack of provisions for
compensating individuals for medical expenses or lost wages if they are
harmed by the vaccine. Without such measures in place, compensation would be
left to employers, insurers, and state worker's compensation plans.
Currently, under the provisions of the Homeland Security Act, the
government, vaccine manufacturers, and the institutions and individuals who
administer the smallpox vaccine are protected from liability; individuals
harmed by the vaccine would have to sue the federal government and prove
negligence to receive compensation. One of the unions, the Service Employees
International Union, said it will advise the 750 000 health care workers who
are among its members not to participate in the vaccination program unless
the Bush administration addresses the compensation issue.
Based on past experience with the smallpox vaccine, for every 1 million
people immunized, between 14 and 52 individuals vaccinated for the first
time could experience serious and potentially life-threatening complications
and 1 or 2 could die.
Additional concerns involve the cost of screening out individuals who
should not be vaccinated because they are particularly susceptible to the
vaccine's potential adverse effects, such as people with eczema, individuals
with weakened immunity such as cancer patients and organ transplantation
recipients, and others. Screening efforts should also determine whether
potential vaccinees could pose a risk to others
for
example, if they live with and could inadvertently infect someone with a
condition that makes them vulnerable to the live vaccinia used in the
vaccine.
Department of Health and Human Services Secretary Tommy Thompson said
that he was working with the White House and key senators to compensate such
individuals for medical expenses, lost wages, and other costs they might
incur from being vaccinated.
EXPERT PANEL URGES MORE DELIBERATION BY GOVERNMENT

The IOM panel also urged the government to "proceed cautiously, allowing
continuous opportunity for adequate and thoughtful deliberation, analysis,
and evaluation." Phase 2 of the program should begin only after the first
phase of the program could be evaluated, and the CDC should use active
surveillance of vaccinees regarding adverse effects, the group said.
However, CDC officials said it would not be necessary to pause between
the two phases because the agency had established a data safety monitoring
board to assess the program on an ongoing basis.
"There is a very active adverse-event monitoring program in place
already," said Walter Orenstein, MD, director of the CDC National
Immunization Program during a press briefing. "In fact, because we are the
ones who control the therapies for a number of these adverse events, we
believe a lot of them will be reported to us for that reason, as well."
"The priority is getting these response teams vaccinated," said CDC
Director Julie L. Gerberding, MD, MPH. "We'll go forward with the larger
group"
the second wave of
vaccinations
"as preparations
evolve," she said. What that will mean in practice is that some states will
likely proceed with the broader ranges of groups
firefighters,
police, emergency medical personnel, and additional health care workers
while
others are still inoculating the smallpox response team members.
As of January 22, CDC shipped kits (containing enough vaccine and the
two-pronged bifurcated needles used to administer the vaccine for 21 600
public health and health care workers) to Connecticut, Nebraska, Vermont,
and Los Angeles County. As of that date, 20 states have requested nearly
100 000 doses of the vaccine.
However, a number of hospitals across the country are declining to
participate in the program for now, citing concerns such as the vaccine's
potential adverse effects, worker's compensation issues, and the possibility
of inadvertant exposure of vulnerable individuals to vaccinia shed by
vaccinated volunteers.
Sen Edward Kennedy, (D, Mass), planned to offer an amendment to a
spending package currently under debate that would allocate $750 million for
a smallpox vaccine compensation fund and provide $850 million to help
states, facing severe budget shortfalls, run their inoculation programs.
The CDC maintains a Web site with up-to-date information for medical
professionals regarding the vaccine itself, the method of vaccination,
contraindications for vaccination, and normal and adverse reactions to the
vaccine at
http://www.bt.cdc.gov/training/smallpoxvaccine/reactions/default.htm.
The Smallpox Vaccine
- Contains live vaccinia, a member of the Orthopoxvirus
family, which includes smallpox (variola), cowpox, others.
- Offers a high level of immunity for 3 to 5 years; protection after
primary vaccination begins to fade after 5 years and is probably
negligible after 20 years.
- When given within 2-3 days after exposure to smallpox, can result
in protection against the disease. May prevent death when given as
late as 4 to 5 days after exposure.
- Causes (based on historical data) potentially life-threatening
reactions in an estimated 14 to 52 people per million who receive the
vaccine.
Source: Centers for Disease Control and Prevention |